<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04676776</url>
  </required_header>
  <id_info>
    <org_study_id>8005</org_study_id>
    <nct_id>NCT04676776</nct_id>
  </id_info>
  <brief_title>Assessing Use Of Mifepristone After Progestin Priming For Use As &quot;Missed Period Pills&quot;</brief_title>
  <official_title>Assessing Use Of Mifepristone After Progestin Priming For Use As &quot;Missed Period Pills&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynuity Health Projects</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cuidado Integral de la Mujer, Gineclinic, S.C.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynuity Health Projects</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the effectiveness and acceptability of a 3-day missed period pill&#xD;
      regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Missed period pills (MPPs) are medications used for uterine evacuation among women with late&#xD;
      menses who have not confirmed pregnancy status. Provision of MPPs could expand reproductive&#xD;
      service options for individuals in a variety of settings. This study will collect data on the&#xD;
      efficacy, safety, and acceptability of a 3-day missed period pill regimen among individuals&#xD;
      with missed menses of 1-10 days&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Simon's two-stage design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of missed period pill regimen</measure>
    <time_frame>Up to 28 days after administration of levonorgestrel</time_frame>
    <description>Proportion of participants not pregnant at follow-up among those who were pregnant at enrollment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of missed period pill regimen</measure>
    <time_frame>Up to 28 days after administration of levonorgestrel</time_frame>
    <description>Proportion of all enrolled participants not pregnant at follow-up (among those who were and were not pregnant at enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness at inducing return of menses within 10 days</measure>
    <time_frame>Up to 10 days after administration of levonorgestrel</time_frame>
    <description>Proportion of participants reporting return of missed menses within 10 days of initiating missed period pill regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of treatment-emergent adverse events and/or side effects (safety and tolerability)</measure>
    <time_frame>Up to 28 days after administration of levonorgestrel</time_frame>
    <description>Proportion of participants who report adverse events and/or side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability of missed period pills</measure>
    <time_frame>Up to 28 days after administration of levonorgestrel</time_frame>
    <description>Proportion of participants who report that the missed period pill service was acceptable or highly acceptable to them</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">139</enrollment>
  <condition>Missed Menstrual Period</condition>
  <arm_group>
    <arm_group_label>Missed period pill regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mg levonorgestrel given on day 1 200 mg mifepristone given on day 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levonorgestrel</intervention_name>
    <description>All participants receive 1.5 mg levonorgestrel on day 1</description>
    <arm_group_label>Missed period pill regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <description>All participants receive 200 mg mifepristone on day 3</description>
    <arm_group_label>Missed period pill regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-49 years&#xD;
&#xD;
          -  General good health&#xD;
&#xD;
          -  Does not want to be pregnant&#xD;
&#xD;
          -  History of regular monthly menstrual cycles (Â±3 days)&#xD;
&#xD;
          -  Missed menses of 1 to 10 days as verified by report of last menstrual period&#xD;
&#xD;
          -  Sexual activity in the past month&#xD;
&#xD;
          -  Willing and able to sign consent forms&#xD;
&#xD;
          -  Willing to return for a follow-up visit&#xD;
&#xD;
          -  Willing to provide a urine sample at enrollment and at follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergies or contraindications to mifepristone&#xD;
&#xD;
          -  Symptoms of or risk factors for ectopic pregnancy, such as vaginal bleeding or&#xD;
             spotting within the past week; unilateral pelvic pain or significant bilateral pelvic&#xD;
             pain within the past week; prior ectopic pregnancy; prior permanent contraception or&#xD;
             other tubal surgery&#xD;
&#xD;
          -  Current use of an IUD, contraceptive implant or injectable&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beverly H Winikoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Holly A Anger</last_name>
    <role>Study Director</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Holly A Anger</last_name>
    <phone>2124481230</phone>
    <email>hanger@gynuity.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manuel Bousieguez</last_name>
    <phone>2124481230</phone>
    <email>mbousieguez@gynuity.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cuidado Integral de la Mujer, Gineclinic, S.C</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karla Figueroa Flores, MD</last_name>
    </contact>
    <investigator>
      <last_name>Karla Figueroa Flores, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2020</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

